Venus Remedies Balance Sheet Health
Financial Health criteria checks 6/6
Venus Remedies has a total shareholder equity of ₹4.9B and total debt of ₹409.1M, which brings its debt-to-equity ratio to 8.3%. Its total assets and total liabilities are ₹6.6B and ₹1.7B respectively. Venus Remedies's EBIT is ₹233.7M making its interest coverage ratio -5.7. It has cash and short-term investments of ₹1.3B.
Key information
8.3%
Debt to equity ratio
₹409.10m
Debt
| Interest coverage ratio | -5.7x |
| Cash | ₹1.34b |
| Equity | ₹4.94b |
| Total liabilities | ₹1.66b |
| Total assets | ₹6.60b |
Recent financial health updates
Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt
Jun 13
Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly
Jun 03Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
May 31Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
Feb 01We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt
Jan 14Is Venus Remedies (NSE:VENUSREM) A Risky Investment?
Sep 22Recent updates
Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why
Sep 17Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%
Jun 14Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt
Jun 13Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%
Mar 14Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)
Oct 31Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly
Jun 03Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)
Jul 15Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
May 31I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease
Mar 30Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge
Feb 24Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
Feb 01Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching
Nov 16Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?
Mar 11We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt
Jan 14Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 23Is Venus Remedies (NSE:VENUSREM) A Risky Investment?
Sep 22Financial Position Analysis
Short Term Liabilities: VENUSREM's short term assets (₹3.9B) exceed its short term liabilities (₹1.0B).
Long Term Liabilities: VENUSREM's short term assets (₹3.9B) exceed its long term liabilities (₹652.1M).
Debt to Equity History and Analysis
Debt Level: VENUSREM has more cash than its total debt.
Reducing Debt: VENUSREM's debt to equity ratio has reduced from 57% to 8.3% over the past 5 years.
Debt Coverage: VENUSREM's debt is well covered by operating cash flow (159.7%).
Interest Coverage: VENUSREM earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 15:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Venus Remedies Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashish Kushwaha | FirstCall Research |
| Nagaraju Airruva | FirstCall Research |